1. Scrip
  2. >>Business
  3. >>Deals

Lilly Adds To Diabetes Pipeline With Protomer Buyout

 
• By Joseph Haas

After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.

Insulin ampoule and a syringe isolated against white background
With its buyout of Protomer, Lilly hopes it can develop a safer, more efficacious insulin

Looking to add to its already substantial diabetes portfolio, Eli Lilly and Company announced on 14 July that it will buy Protomer Technologies, which is working on glucose-sensitive insulins, less than a year after making an equity investment in the Pasadena, CA-based biotech. No specific financial terms were disclosed, but Lilly said Protomer shareholders could realize more than $1bn from the transaction if specified development and commercial milestones are achieved.

Protomer announced an equity financing in November from the Juvenile Diabetes Research Foundation, which followed Lilly’s investment that gave the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.